Biotech startup NanoZymeX receives seed funding
NanoZymeX is a biotech startup developing advanced enzyme-replacement therapies with proprietary lipid-based nanoparticles for rare genetic diseases. The company has secured CHF 150,000 in startup funding from Venture Kick.
25 March 2026
Enzyme replacement therapies treat rare genetic disorders, but their effectiveness is often limited by poor delivery to target tissues. Immune responses to repeated treatments can also reduce long-term effectiveness.
The biotech startup NanoZymeX is developing a lipid nanoparticle platform to deliver therapeutic enzymes directly into target cells and lysosomes. This approach improves intracellular delivery, reduces immune reactions, and increases functional activity where needed most.
Early preclinical studies demonstrate strong delivery efficiency and enhanced enzyme activity in relevant tissues. The technology targets lysosomal storage disorders, including Pompe disease, which represent a multibillion-dollar therapeutic market.
Spin-off from the University of Basel
The University of Basel spin-off is led by Boris Sevarika, Margarita C. Dinamarca and Eva Hemmrich, who bring complementary expertise in formulation development, neurobiology, and regulatory science.
“The support from Venture Kick comes at a critical moment when scientific discoveries need to transition into real companies,” highlighted Boris Sevarika, co-founder of NanoZymeX. “This type of early funding provides the flexibility needed for company building, business development, and preparing the next stages of financing. It fills a crucial gap between academic research and venture-backed biotech development.”
The Venture Kick initiative provides seed funding to Swiss startups and a structured path for business development. The CHF 150,000 will enable NanoZymeX to advance its lipid nanoparticle technology, conduct further preclinical studies, and prepare for scalable manufacturing. These efforts will support future fundraising and the transition to clinical trials.
This text is based on a press release from Venture Kick.